Vedana Therapeutics Launches With $46 Million Series A Financing to Advance Next-Generation Migraine Therapies
Summary
Vedana Therapeutics launched out of stealth with $46 million in Series A financing. The company plans to use the capital to advance next-generation migraine therapies, including a lead anti-PACAP antibody and a bispecific program targeting PACAP and CGRP. Its team includes executives and advisors with deep experience in migraine drug discovery, clinical development, and commercialization. The financing was co-led by Westlake BioPartners and Canaan Partners, with additional participation from Dawn Biopharma and Alexandria Venture Investments.
Funding
Amount
$46.0M
Total raised
Date
June 17, 2026
Announcement date
Investors
Westlake Village BioPartners, Alexandria Venture Investments, Canaan Partners
Lead investors
Company
vedanatx.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected